Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The present studies were conducted to determine if increasing central levels of the neurotrophic factor insulin-like growth factor-1 (IGF-I) either directly or indirectly produces anxiolytic and antidepressant-like effects in the mouse. Central levels of IGF-I can be increased directly, by administering IGF-I, or indirectly by blocking the insulin-like growth factor binding proteins (IGFBPs). The IGFBP family has the unique ability to regulate IGF-I levels by sequestering IGF-I into an inactive complex. Therefore, an IGFBP inhibitor increases the level of IGF-I available to bind to its receptor. Intracerebroventricular (icv) administration of the nonspecific IGFBP inhibitor NBI-31772 (10-30 microg) increases the number of punished crossings in the four-plate test and NBI-31772 (0.3-10 microg) increases time spent in the open quadrant of the elevated zero maze (EZM), indicative of anxiolytic-like effects. NBI-31772 (3-30 microg) also decreases immobility time in the tail suspension test, indicative of antidepressant-like effects. Similarly, icv administration of IGF-I (0.1 microg) produces anxiolytic-like effects in the four-plate test and IGF-1 (0.3-1 microg) produces anxiolytic-like effects in the EZM. IGF-I (10 microg) also produces antidepressant-like effects in the tail suspension test. Coadministration of the IGF-I receptor antagonist JB1 with NBI-31772 or IGF-I blocks the anxiolytic-like and antidepressant-like effects of these compounds. These results suggest that NBI-…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, an increase of peripheral IGF-1 by direct injection of IGF-1 or inhibition of IGF-1 binding protein displayed anxiolytic and antidepressant effects in rodents (Duman et al. 2009; Hoshaw et al. 2005; Malberg et al. 2007; Park et al. 2011)”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Malberg et al. 2007
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“Despite the high prevalence of depressive and anxiety disorders in the population (Berton and Nestler, 2006; Kessler et al, 2005; Malberg and Schechter, 2005), our understanding of the mechanisms by which antidepressant and anxiolytic drugs produce their effects are limited.”
BackgroundValidation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822 · cited 1×
“Compounds that increase the percentage time an animal spends in the open quadrants Neuropsychopharmacology of the EZM, compared to the closed quadrants, are considered to exhibit anxiolytic-like activity (Kash et al, 1999; Pellow et al, 1985).”
BackgroundThe tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534 · cited 1×
“The procedure followed in this study is a variant of the one originally described by Steru et al (1985).”
MethodNestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111 · cited 1×
“This difference in time course between the acute behavioral effects and the chronic administration necessary for cell proliferation has also been seen with clinically effective antidepressant such as fluoxetine (Malberg et al, 2000).”
BackgroundSelf-citationNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“Despite the high prevalence of depressive and anxiety disorders in the population (Berton and Nestler, 2006; Kessler et al, 2005; Malberg and Schechter, 2005), our understanding of the mechanisms by which antidepressant and anxiolytic drugs produce their effects are limited.”
BackgroundThe Somatomedin Hypothesis: 2001
Le Roith, D., Bondy, C., Yakar, S., Liu, J.-L., & Butler, A. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0419 · Cited by 1,257 · cited 1×
“IGF-I was first named ‘somatomedin C’ owing to its ability to mediate the effect of somatotropin (growth hormone) (Le Roith et al, 2001).”
BackgroundBrunet, A., Datta, S. R., & Greenberg, M. E. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00211-7 · Cited by 1,188 · cited 1×
“This receptor signaling pathway activates both the Ras/mitogen-activated protein kinase pathway and the PI3 kinase–AKT pathways (Brunet et al, 2001; Ye and D’Ercole, 2006).”
BackgroundPeripheral Infusion of IGF-I Selectively Induces Neurogenesis in the Adult Rat Hippocampus
Åberg, M. A. I., Åberg, N. D., Hedbäcker, H., Oscarsson, J., & Eriksson, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02896.2000 · Cited by 852 · cited 2×
“It has been shown that IGF-I produces increases in cell proliferation and neurogenesis in vivo (Aberg et al, 2000).”
BackgroundShepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J., & Dourish, C. T. (1994) · Psychopharmacology · doi:10.1007/bf02244871 · Cited by 739 · cited 2×
“The EZM is a modification of the elevated plus maze and consists of a circular platform (outer diameter approximately 60 cm, width 5 cm) that is elevated 55 cm above the floor, and made of black Perspex (Shepherd et al, 1994).”
Background
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Mechanisms and Functional Implications of Adult Neurogenesis
Zhao, C., Deng, W., & Gage, F. H. (2008) · Cell · doi:10.1016/j.cell.2008.01.033 · Cited by 3,007
“Similarly, infusion of IGF1 elicits anxiolytic and antidepressant-like effects in behavioral tests (Malberg et al., 2007), and systematic administration of IGF1 increases SGZ neurogenesis (see references in Duman and Monteggia, 2006).”
Sex-Specific Programming of Offspring Emotionality after Stress Early in Pregnancy
Mueller, B. R., & Bale, T. L. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1424-08.2008 · Cited by 988
“Reductions in growth factors have been linked to affective and neurodevelopmental disorders (Malberg et al., 2007).”
BackgroundFunctional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
“Chronic antidepressant administration increases IGF-1 expression in the rat brain (Khawaja et al, 2004), and IGF-1 regulates adult hippocampal neurogenesis (Anderson et al, 2002) and produces antidepressant behavioral responses (Hoshaw et al, 2005; Malberg et al, 2007).”
BackgroundNeurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Burgdorf, J., Panksepp, J., & Moskal, J. R. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.11.011 · Cited by 258
Nutritional Aspects of Depression
Lang, U. E., Beglinger, C., Schweinfurth, N., Walter, M., & Borgwardt, S. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430229 · Cited by 239
Sex differences in prenatal epigenetic programing of stress pathways
Bale, T. L. (2011) · Stress · doi:10.3109/10253890.2011.586447 · Cited by 239
O’Connor, J. C., McCusker, R. H., Strle, K., Johnson, R. W., Dantzer, R., & Kelley, K. W. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.09.010 · Cited by 238
“and yet inversely related to life span is further perpetuated by recent studies demonstrating beneficial effects of IGF-I in the treatment of behavioral characteristics of depression [23,24].”
BackgroundA spinal microglia population involved in remitting and relapsing neuropathic pain
Kohno, K., Shirasaka, R., Yoshihara, K., Mikuriya, S., Tanaka, K., Takanami, K., Inoue, K., Sakamoto, H., Ohkawa, Y., Masuda, T., et al. (2022) · Science · doi:10.1126/science.abf6805 · Cited by 211
Duman, R. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/rsduman · Cited by 210
Sex-specificity in transgenerational epigenetic programming
Dunn, G. A., Morgan, C. P., & Bale, T. L. (2011) · Hormones and Behavior · doi:10.1016/j.yhbeh.2010.05.004 · Cited by 198
“Reductions in growth factors have been linked to affective and neurodevelopmental disorders, and IGFBP-1 is known to downregulate genes involved in embryonic growth (Kajimura et al., 2005; Malberg et al., 2007).”
Aleman, A., & Torres-Alemán, I. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.07.008 · Cited by 184
Examining the Intersection of Sex and Stress in Modelling Neuropsychiatric Disorders
Goel, N., & Bale, T. L. (2009) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2009.01843.x · Cited by 182
Is increased antidepressant exposure a contributory factor to the obesity pandemic?
Lee, S. H., Paz-Filho, G., Mastronardi, C., Licinio, J., & Wong, M.-L. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.25 · Cited by 139
Park, S.-E., Dantzer, R., Kelley, K. W., & McCusker, R. H. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-12 · Cited by 158
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
Ring, R. H., Schechter, L. E., Leonard, S. K., Dwyer, J. M., Platt, B. J., Graf, R., Grauer, S. M., Pulicicchio, C. M., Resnick, L., Rahman, Z. U., et al. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.016 · Cited by 157
“The TST model used in our laboratory has been described previously (Malberg et al., 2007).”
MethodSelf-citationMicroglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders
Leonard, S. K., Dwyer, J. M., Rizzo, S. J. S., Platt, B. J., Logue, S. F., Webb, S. J. N., Malberg, J. E., Beyer, C. E., Schechter, L. E., Rosenzweig-Lipson, S. J., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1080-4 · Cited by 149
“(1985) as previously described (Malberg et al. 2007; Ring et al. 2006).”
MethodInfluentialSelf-citationAlessi, J., de Oliveira, G. B., Franco, D. W., Brino do Amaral, B., Becker, A. S., Knijnik, C. P., Kobe, G. L., de Carvalho, T. R., Telo, G. H., Schaan, B. D., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00584-6 · Cited by 131
Wada, A. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09r02cr · Cited by 128
Baldini, S., Restani, L., Baroncelli, L., Coltelli, M., Franco, R., Cenni, M. C., Maffei, L., & Berardi, N. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3541-12.2013 · Cited by 112
“…used, both intracerebroventricularly and subcutaneously, to block IGF-1 action and to prevent systemic IGF-1 from crossing the blood–brain barrier (Fernandez et al., 1997; Carro et al., 2000, Malberg et al., 2007; Hoshaw et al., 2008; Guzzetta et al., 2009; Brock et al., 2011; Witty et al., 2013).”
BackgroundDuman, C. H., Schlesinger, L., Terwilliger, R., Russell, D. S., Newton, S. S., & Duman, R. S. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.11.016 · Cited by 123
“Our results are consistent with the reported antidepressant-like effect of IGFI following central administration and with a depressant-like effect seen in mutant mice that are deficient in serum IGF-I [28,34,53].”
ResultMitschelen, M., Yan, H., Farley, J. A., Warrington, J. P., Han, S., Hereñú, C. B., Csiszar, A., Ungvari, Z., Bailey-Downs, L. C., Bass, C. E., et al. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.04.032 · Cited by 103
“…role for IGF-1 in the amelioration of anxiety, depression, and memory deficits (Carro et al., 2000; Hoshaw et al., 2005; Lupien et al., 2003; Malberg et al., 2007; Markowska et al., 1998; Nieves-Martinez et al., 2010; Trejo et al., 2008) which may be due to the reported effects of IGF-1 on…”
InfluentialQuipildor, G. F., Mao, K., Hu, Z., Novaj, A., Cui, M., Gulinello, M. E., Branch, C. A., Gubbi, S., Patel, K., Moellering, D. R., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00065-3 · Cited by 90
Squassina, A., Costa, M., Congiu, D., Manchia, M., Angius, A., Deiana, V., Ardau, R., Chillotti, C., Severino, G., Calza, S., et al. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.04.004 · Cited by 80
IGFBP-2 Signaling in the Brain: From Brain Development to Higher Order Brain Functions
Khan, S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00822 · Cited by 86
Goldstein, J. M., Handa, R. J., & Tobet, S. A. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.12.001 · Cited by 77
“Animal models of chronic stress in IGF-1 treated mice (Duman et al., 2009) and IGF-1 KO mice had a significant impact on reducing immobility, underscoring its antidepressant-like properties (Hoshaw et al., 2005; Malberg et al., 2007; Duman et al., 2009).”
Duric, V., & Duman, R. S. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1020-7 · Cited by 79
Gelenberg, A. J., Thase, M. E., Meyer, R. E., Goodwin, F. K., Katz, M. M., Kraemer, H. C., Potter, W. Z., Shelton, R. C., Fava, M., Khan, A., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1001 · Cited by 79
Adult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action?
Eliwa, H., Belzung, C., & Surget, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.005 · Cited by 78
Burgdorf, J. S., Kroes, R. A., Beinfeld, M. C., Panksepp, J., & Moskal, J. R. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.03.045 · Cited by 78
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
“Although much attention remains directed on the specific role of BDNF in the hippocampus and frontal cortex, there is new evidence of the involvement of several additional neurotrophic factors including fibroblast growth factor (FGF) [87], insulin-like growth factor (IGF-1) [88], and vasoendothelial growth factor (VEG…”
Park, S.-E., Lawson, M., Dantzer, R., Kelley, K. W., & McCusker, R. H. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-179 · Cited by 65
Possible contribution of IGF-1 to depressive disorder
Szczęsny, E., Ślusarczyk, J., Głombik, K., Budziszewska, B., Kubera, M., Lasoń, W., & Basta-Kaim, A. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71523-8 · Cited by 68
“Most data are very consistent and show that IGF-1 treatment exerts antidepressant like-activity by normalization of behavioral disturbances in various animal models of depression [14, 15, 22, 32, 33].”
BackgroundHippocampal Gene Expression Is Highly Responsive to Estradiol Replacement in Middle-Aged Female Rats
Sárvári, M., Kalló, I., Hrabovszky, E., Solymosi, N., Rodolosse, A., Vastagh, C., Auer, H., & Liposits, Z. (2015) · Endocrinology · doi:10.1210/en.2015-1109 · Cited by 61
Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission
Hoshaw, B. A., Hill, T. I., Crowley, J. J., Malberg, J. E., Khawaja, X., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.023 · Cited by 60
“Similar effects were produced by JB1 pretreatment on the antidepressant and anxiolytic effects of IGF-1 in the mouse (Malberg et al., 2007).”
BackgroundSelf-citationAckermann, T. F., Hörtnagl, H., Wolfer, D. P., Colacicco, G., Sohr, R., Lang, F., Hellweg, R., & Lang, U. E. (2008) · Cellular Physiology and Biochemistry · doi:10.1159/000185557 · Cited by 53
Tu, K.-Y., Wu, M.-K., Chen, Y.-W., Lin, P.-Y., Wang, H.-Y., Wu, C.-K., & Tseng, P.-T. (2016) · Medicine · doi:10.1097/md.0000000000002411 · Cited by 45
“Studies Included in Each Meta-Analysis A total of 27 articles reached the screening stage, of which 4 were excluded because they focused on peripheral IGF-1 levels only in MDD patients without comparing the effects of treatment(31) or comparisons with healthy controls, 4 that focused on topics not related to BD or MDD…”
Bot, M., Milaneschi, Y., Penninx, B. W. J. H., & Drent, M. L. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.028 · Cited by 50
“xperimental studies in rats and mice generally show that increasng IGF-I levels – either centrally and peripherally – result in educed immobility (Duman et al., 2009; Hoshaw et al., 2005; alberg et al., 2007) and behavior indicative of lower anxiety Malberg et al.”
Genes differentially expressed in CB1 knockout mice: Involvement in the depressive-like phenotype
Aso, E., Ozaita, A., Serra, M.-À., & Maldonado, R. J. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.007 · Cited by 50
“IGF binding proteins reduce IGF1 signaling by sequestering IGF1 into an inactive complex (Malberg et al., 2007).”
BackgroundKarachaliou, F.-E., Karavanaki, K., Simatou, A., Tsintzou, E., Skarakis, N., & Kanaka‐Gantenbein, C. (2021) · HORMONES · doi:10.1007/s42000-021-00306-1 · Cited by 47
Regulation of adult hippocampal neurogenesis: relevance to depression
Vaidya, V. A., Fernandes, K., & Jha, S. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.7.853 · Cited by 45
Niciu, M. J., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A. (2013) · CNS Spectrums · doi:10.1017/s1092852913000059 · Cited by 43
Munive, V., Santi, A., & Torres-Aleman, I. (2016) · Scientific Reports · doi:10.1038/srep25969 · Cited by 43
Santi, A., Bot, M., Aleman, A., Penninx, B. W. J. H., & Aleman, I. T. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0196-5 · Cited by 44
Llorens-Martín, M., Jurado-Arjona, J., Bolós, M., Pallas-Bazarra, N., & Ávila, J. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.12.019 · Cited by 43
“With regard to the psycho-neuroendocrine system, the IGF-I and VEGF systems are heavily involved in the pathophysiology of MD, as reflected by the fact that the administration of IGF-I has antidepressant effects (Malberg et al., 2007), the decreased levels of IGF-I have been related to depressive symptoms (Mitschelen…”
Safian, D., Morais, R. D. V. S., Bogerd, J., & Schulz, R. W. (2016) · Endocrinology · doi:10.1210/en.2016-1315 · Cited by 43
“In mice, NBI-31772 produced neuropharmacological effects similar to those observed after experimentally increasing circulating IGF1 levels (50), and in vivo administration of NBI-31772 enhanced muscle regeneration (51).”
Decreased plasma concentrations of BDNF and IGF-1 in abstinent patients with alcohol use disorders
García‐Marchena, N., Silva‐Peña, D., Martín, A. I., Villanúa, M. Á., Araos, P. F., Pedraz, M., Maza-Quiroga, R. M., Romero‐Sanchiz, P., Rubio, G., Castilla‐Ortega, E., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187634 · Cited by 42
A novel 5HT3 receptor–IGF1 mechanism distinct from SSRI-induced antidepressant effects
Kondo, M., Koyama, Y., Nakamura, Y., & Shimada, S. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.87 · Cited by 41
Signaling mechanisms involved in the acute effects of estradiol on 5-HT clearance
Benmansour, S., Privratsky, A. A., Adeniji, O. S., & Frazer, A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571300165x · Cited by 40
“Acute intraventricular delivery of IGF-1 to mice had an antidepressant-like effect in the tail suspension test (Malberg et al., 2007).”
BackgroundPDE11A negatively regulates lithium responsivity
Pathak, G., Agostino, M. J., Bishara, K., Capell, W. R., Fisher, J. L., Hegde, S., Ibrahim, B. A., Pilarzyk, K., Sabin, C., Tuczkewycz, T., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.155 · Cited by 37
Pedraz, M., Martín, A. I., García‐Marchena, N., Araos, P. F., Serrano, A., Romero‐Sanchiz, P., Suárez, J., Castilla‐Ortega, E., Barrios, V., Campos‐Cloute, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118610 · Cited by 35
“This peptide is also involved in the pathogenesis and evolution of psychiatric disorders in preclinical models [21,22] and clinical cases in old [23] and young [24] individuals.”
BackgroundPereira, A. C., McQuillin, A., Puri, V., Anjorin, A., Bass, N. J., Kandaswamy, R., Lawrence, J., Curtis, D., Sklar, P. B., Purcell, S., et al. (2011) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31153 · Cited by 34
“In two recent studies, central administration of IGF1 in mice has shown to have an antidepressant-like effect [Hoshaw et al., 2005; Malberg et al., 2007].”
BackgroundTreatment With Antidepressants Increases Insulin-Like Growth Factor-I in Cerebrospinal Fluid
Schilling, C., Blum, W. F., Heuser, I., Paslakis, G., Wudy, S. A., & Deuschle, M. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189d86 · Cited by 29
Piubelli, C., Gruber, S. H. M., Khoury, A. E., Mathé, A. A., Domenici, E., & Carboni, L. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.003 · Cited by 25
“, 2009), and the ability of IGF1 itself to display antidepressant activity in rodents through activation of neurotrophic events (Duman et al., 2009; Hoshaw et al., 2005; Malberg et al., 2007).”
BackgroundBasta‐Kaim, A., Szczęsny-Małysiak, E., Głombik, K., Ślusarczyk, J., Trojan, E., Tomaszewski, K. A., Budziszewska, B., Kubera, M., & Lasoń, W. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.010 · Cited by 25
Brady, L. S., Winsky, L., Goodman, W. K., Oliveri, M. E., & Stover, E. S. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.125 · Cited by 25
“…Group is focusing on central growth factors and cell proliferation as a novel mechanism for developing treatments for depression and anxiety (Malberg et al, 2007; CRISP abstract, http://crisp.cit.nih.gov/crisp/CRISP_LIB. getdoc?textkey=7234053&p_grant_num=5U01MH072832-03…”
BackgroundNiciu, M. J., Ionescu, D. F., Mathews, D. C., Richards, E. M., & Zarate, C. A. (2013) · CNS Spectrums · doi:10.1017/s1092852913000138 · Cited by 23
Lucia-Casadonte, C., Brown, J. B., Strople, J. A., Neighbors, K., Fei, L., & Alonso, E. M. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002057 · Cited by 22
Tian, N., Kanno, T., Jin, Y., & Nishizaki, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.041 · Cited by 21
McIntyre, R. S., Vagic, D., Swartz, S. A., Soczynska, J. K., Woldeyohannes, H. O., Voruganti, L. P., & Konarski, J. Z. (2008) · CNS Drugs · doi:10.2165/00023210-200822060-00001 · Cited by 21
Dobolyi, Á., & Lékó, A. H. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.12.002 · Cited by 18
Okamoto, N., Yoshino, K., Kitagawa, S., Fujii, R., Hamada, S., Ikenouchi, A., Konishi, Y., Ueda, N., Eto, Y., Tsutsumi, Y., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.653802 · Cited by 17
“This peptide is also involved in the pathogenesis and evolution of psychiatric disorders, including major depression and schizophrenia, in preclinical (7, 8) and clinical studies (9–11).”
BackgroundInsulin-like growth factor binding proteins inhibit oocyte maturation of zebrafish
Li, J., Wang, Y., Kang, T., Li, X., & Niu, C. (2019) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2019.06.002 · Cited by 16
Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study
Rosso, G., Zanardini, R., Chiodelli, D. F., Ferrari, C., Gennarelli, M., & Bocchio‐Chiavetto, L. (2016) · Neuropsychobiology · doi:10.1159/000446918 · Cited by 16
Schindler, N., Mayer, J., Saenger, S., Gimsa, U., Walz, C., Brenmoehl, J., Ohde, D., Wirthgen, E., Tuchscherer, A., Russo, V., et al. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.11.003 · Cited by 14
“(2007), who demonstrated that displacement of IGF-I from its binding proteins, presumably resulting in free IGF-I, produces anxiolytic and antidepressant effects in mice [24], while the lack of peripheral or hippocampal IGF-I is associated with a depressive phenotype in adult mice [27].”
BackgroundLékó, A. H., Cservenák, M., Szabó, É. R., Hanics, J., Alpár, A., & Dobolyi, Á. (2017) · Scientific Reports · doi:10.1038/s41598-017-03645-5 · Cited by 14
Dunacka, J., Grembecka, B., Majkutewicz, I., & Wrona, D. (2025) · Pharmaceuticals · doi:10.3390/ph18040527 · Cited by 13
“ICV administration of IGF-1 was performed according to the method and a dose of IGF-1 described previously [68,69].”
Schweinfurth, N., Walter, M., Borgwardt, S., & Lang, U. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-19821-7_18 · Cited by 13
Neurotrophic Factors and Antidepressant Action: Recent Advances
O’Leary, O. F., & Ċastrén, E. (2010) · Modern trends in psychiatry · doi:10.1159/000319514 · Cited by 13
Beyer, C., Lin, Q., Platt, B. J., Malberg, J. E., Hornby, G. A., Sullivan, K., Smith, D., Lock, T., Mitchell, P., Hatzenbuhler, N., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00146.x · Cited by 10
“The mouse four-plate assay is routinely used as preclinical model of anxiety (Hascoet et al., 2000; Ring et al., 2006; Malberg et al., 2007).”
MethodSelf-citationBiomarkers for Major Depressive Disorder: Economic Considerations
Bogavac‐Stanojević, N., & Lakić, D. (2016) · Drug Development Research · doi:10.1002/ddr.21330 · Cited by 8
“Several studies suggested that IGF-1 [Hoshaw et al., 2005; Malberg et al., 2007], brain-derived neurotrophic factor [Huang et al., 2008] and vascular endothelial growth factor [Greene et al., 2009] could contribute to elucidating antidepressant treatment responses.”
BackgroundEpigenetic regulation of BDNF-TrkB signaling in the pathophysiology and treatment of mood disorders
Boulle, F. (2013) · Research Publications (Maastricht University) · doi:10.26481/dis.20131129fb · Cited by 8
García-Ríos, R. I., Mora-Pérez, A., & Soria-Fregozo, C. (2017) · InTech eBooks · doi:10.5772/intechopen.69786 · Cited by 7
Alterations in Neural Structures as Risk Factors for Depression
Ramasubbu, R., & MacQUEEN, G. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-08-045078-0.00003-4 · Cited by 7
The GH/IGF-1-Axis in Psychopathological Functions
Auer, M. K. (2012) · The Open Endocrinology Journal · doi:10.2174/1874216501206010062 · Cited by 5
Narayanaswamy, J. C., Jose, D. A., Shivakumar, V., Shrinivasa, B., Kaur, M., Kalmady, S. V., Venkatasubramanian, G., & Reddy, Y. C. J. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.03.013 · Cited by 5
“This observation of IGF-1 predicting antiobsessive action of SSRI is in line with the previous literature derived from animal models demonstrating potential role for IGF-1 in antidepressant and anxiolytic actions (Grunbaum-Novak et al., 2008; Hoshaw et al., 2005; Malberg et al., 2007).”
MethodResultResearch Progress on the Molecular Mechanism by Which Depression Affects Bone Metabolism
Gao, H., Huang, C., Zhao, K., Chen, X., Zhang, X., Deng, Y., Liu, Z., & Duan, D. D. (2020) · DNA and Cell Biology · doi:10.1089/dna.2019.5284 · Cited by 5
“In metabolic disorders, the level of IGF-1 in the central nervous system and peripheral blood of depressed patients is higher than that of the healthy population (Malberg et al. , 2007), and this may have an uncharac-teristic positive effect on bone metabolism.”
Tabęcka-Łonczyńska, A., Mytych, J., Sołek, P., Kulpa-Greszta, M., Jasiewicz, P., Sowa-Kućma, M., Stachowicz, K., & Koziorowski, M. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151685 · Cited by 5
Becker, M., Abaev, K., Pinhasov, A., & Ornoy, A. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113866 · Cited by 5
Leonard, B. E., & Arıcıoğlu, F. (2020) · Psychiatry and Clinical Psychopharmacology · doi:10.5455/pcp.20200215032026 · Cited by 4
Kucharska–Mazur, J., Ratajczak, M. Z., & Samochowiec, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-31206-0_8 · Cited by 4
Antidepressant-like effects of trophic factor receptor signaling
Sathyanesan, M., & Newton, S. S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.958797 · Cited by 4
“As the levels of free IGF1 are regulated by specific IGF binding proteins (IGFBPs), antidepressant effects can be produced by inhibiting IGFBP association with IGF and thereby elevating the levels of IGF1 available for receptor binding (Malberg et al., 2007).”
BackgroundHascoët, M., & Bourin, M. (2011) · Neuromethods · doi:10.1007/978-1-61779-313-4_8 · Cited by 4
Li, C., Wang, Z., Ye, X., Lv, J., Chen, F., Zhang, Y., Liu, J., Li, X., Duan, J., Wang, Y., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1692751 · Cited by 3
Dunacka, J., Grembecka, B., & Wrona, D. (2025) · Cells · doi:10.3390/cells14151189 · Cited by 3
“In addition, other studies demonstrated that increasing the central level of IGF-1 by ICV injections of its binding protein inhibitor produced anxiolytic-like and antidepressant-like behavioral effects in the mouse in vivo, similar to IGF-1 administration [39].”
Neurogenic Basis of Antidepressant Action: Recent Advances
Tanti, A., & Belzung, C. (2010) · Modern trends in psychiatry · doi:10.1159/000319515 · Cited by 3
Omam, J. P. O., Mbouh, S., Kandeda, A. K., Koubé, J., Moussa, D. M., Minkoulou, M. D. Z., Goufani, R. B. A., Mbom, A., Moto, F. C. O., & Bum, E. N. (2023) · American Journal of Psychiatry and Neuroscience · doi:10.11648/j.ajpn.202311014.11 · Cited by 3
Levy, M. J. F. (2017) · theses.fr (ABES) · doi:10.70675/be792343za725z4b2czb8c5z8a26a8113d23 · Cited by 3
Alessi, J., de Oliveira, G. B., Franco, D. W., do Amaral, B. B., Becker, A. S., Knijnik, C. P., Kobe, G. L., de Carvalho, T. R., Teló, G. H., Schaan, B. D., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3606443 · Cited by 3
Karakılıç, A., Kızıldağ, S., Yuce, Z., Seval, Y., Kandiş, S., Bozan, H. R., Koç, B., Güvendi, G., Ateş, M., İnan, S., et al. (2022) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2022-015 · Cited by 2
“For in‑ stance, increasing IGF‑1 levels resulted in anxiolyt‑ ic effects in both in vitro and in vivo assays (Malberg et al., 2007).”
BackgroundPhysical Exercise Benefits Cognition: A Narrative Review of Evidence and Possible Mechanisms
Wang, T.-F., Mee-inta, O., & Kuo, Y. (2025) · Advances in neurobiology · doi:10.1007/978-981-95-0066-6_7 · Cited by 2
de Almeida, R., Neto, J. H., & da Silva, E. E. P. (2021) · Debates em Psiquiatria · doi:10.25118/2763-9037.2021.v11.221 · Cited by 1
“221 hipocampal [10], tendo ainda efeitos antidepressivos [11, 12].”
BackgroundSerum IGF-1 and anxiety trajectories in Parkinson's disease
Chen, S., Niu, Y.-X., Li, C.-H., Xiang, X.-F., Shao, J.-Y., Hong-qi, Y., Ma, K., & Zhang, J.-W. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111683 · Cited by 1
ROLE OF INSULIN-LIKE GROWTH FACTOR IN DEPRESSION: A REVIEW
Patel, R. M., & Rana, D. G. (2021) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.1203124 · Cited by 1
Proteomics-based Investigation of Substrates for the Leishmania mexicana Deubiquitinase DUB2
Antoniou, S. (2023) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Intrinsic and extrinsic mechanisms of corticospinal axon regeneration
Hollis, E. R., II (2008) · eScholarship (California Digital Library)
Proteome Effects of Antidepressant Medications
Carboni, L., Piubelli, C., & Domenici, E. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7197-5_15
The Effects of Early-Life Exercise on Neurotrophic Factor Expression Throughout the Lifespan
Bouchet, C. A. (2014) · CU Scholar (University of Colorado Boulder)
Metadata
- Authors
- Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S.
- Affiliations
- Wyeth (US)
- University of Pennsylvania (US)
- Corresponding author
- Malberg, Jessica E
- Venue
- Neuropsychopharmacology
- Published
- 2007-03-07
- Volume
- 32
- Issue
- 11
- Pages
- 2360-2368
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1977606691
- Cited by
- 101
- References
- 47
- Citations by year
- 2026: 2 · 2025: 4 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 9 · 2015: 6 · 2014: 4 · 2013: 9 · 2012: 3
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH 72832, U01MH072832)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- insulin-like growth factor I, anxiolytic effects, antidepressant effects, IGF-1 receptor, neurotrophic factors, depression, anxiety, intracerebroventricular administration, elevated zero maze, tail suspension test, four-plate test
- MeSH terms
- Analysis of Variance, Animals, Antidepressive Agents, Anxiety, Avoidance Learning, Behavior, Animal, Catechols, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Interactions, Enzyme Inhibitors, Gene Expression Regulation, Injections, Intraventricular, Insulin-Like Growth Factor I, Isoquinolines, Male, Motor Activity, Insulin-Like Growth Factor Binding Proteins, Hindlimb Suspension, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.